Disease
Acute Myeloid Leukemia
An aggressive hematologic malignancy of myeloid progenitor cells, primarily affecting older adults and treated with molecularly stratified induction, consolidation, maintenance, and relapse regimens.
Total attributable cost
$4.3B
$190,305/patient
Drug spend
Not yet sourced
All stages, newly diagnosed (2026 incidence estimate) · US